DEFINE - a Randomized, Open-Label Trial of the Inhaled Galectin-3 Inhibitor GB0139 in Hospitalized Patients with Moderate-to-Severe COVID-19

被引：0
|
作者：
Gaughan, E. [1 ]
Sethi, T. [2 ]
Quinn, T. [1 ]
Hirnani, N. [1 ]
Mills, A. [3 ]
Bruce, A. M. [1 ]
Mackinnon, A. [2 ]
Aslanis, V. [2 ]
Li, F. [1 ]
O'Connor, R. [1 ]
Dear, J. [4 ]
Akram, A. R. [1 ]
Koch, O. [5 ]
Wang-Jairaj, J. [2 ]
Slack, R. J. [2 ]
Gravelle, L. [2 ]
Lindmark, B. [2 ]
Dhaliwal, K. [1 ]
机构：
[1] Univ Edinburgh, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland
[2] Galecto Inc, Copenhagen, Denmark
[3] Explorist, Belfast, Antrim, North Ireland
[4] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland
[5] NHS Lothian, Infect Dis Dept, Edinburgh, Midlothian, Scotland
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2022年 / 205卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3127
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia
    Khamis, Faryal
    Al Naabi, Hanan
    Al Lawati, Adil
    Ambusaidi, Zaiyana
    Al Sharji, Mariam
    Al Barwani, Umkulthum
    Pandak, Nenad
    Al Balushi, Zakariya
    Al Bahrani, Maher
    Al Salami, Issa
    Al-Zakwani, Ibrahim
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 102 : 538 - 543
  • [22] Efficacy of Favipiravir in the Treatment of Moderate COVID-19 Patients: A Randomized, Open-label, Controlled Clinical Trial
    Tehrani, Shabnam
    Yadegarynia, Davood
    Bagherzade, Afshin
    Gachkar, Latif
    Keyvanfar, Amirreza
    MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, 2022, 11
  • [23] Azvudine and nirmatrelvir-ritonavir in hospitalized patients with moderate-to-severe COVID-19: Emulation of a randomized target trial
    Zhou, Yiling
    Liu, Yi
    Jiang, Li
    Zhang, Renqing
    Zhang, Huohuo
    Shi, Qingyang
    Yang, Zhirong
    Mao, Yi
    Liu, Sha
    Yang, Zhibo
    Ding, Jialin
    Zhou, Yongzhao
    Ren, Bi
    He, Liping
    Zhao, Xing
    Li, Weimin
    Li, Sheyu
    Liu, Dan
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (12)
  • [24] A phase 2a, open-label pilot study of the galectin-3 inhibitor GR-MD-02 for the treatment of moderate-to-severe plaque psoriasis
    Ritchie, Simon
    Neal, Danielle
    Shlevin, Harold
    Allgood, Adam
    Traber, Peter
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (04) : 753 - 755
  • [25] An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients
    Rea-Neto, Alvaro
    Bernardelli, Rafaella Stradiotto
    Dzivielevski Camara, Bruna Martins
    Reese, Fernanda Baeumle
    Oliveira Queiroga, Marcos Vinicius
    Oliveira, Mirella Cristine
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [26] An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients
    Álvaro Réa-Neto
    Rafaella Stradiotto Bernardelli
    Bruna Martins Dzivielevski Câmara
    Fernanda Baeumle Reese
    Marcos Vinicius Oliveira Queiroga
    Mirella Cristine Oliveira
    Scientific Reports, 11
  • [27] A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19
    Doi, Yohei
    Hibino, Masaya
    Hase, Ryota
    Yamamoto, Michiko
    Kasamatsu, Yu
    Hirose, Masahiro
    Mutoh, Yoshikazu
    Homma, Yoshito
    Terada, Masaki
    Ogawa, Taku
    Kashizaki, Fumihiro
    Yokoyama, Toshihiko
    Koba, Hayato
    Kasahara, Hideki
    Yokota, Kazuhisa
    Kato, Hideaki
    Yoshida, Junichi
    Kita, Toshiyuki
    Kato, Yasuyuki
    Kamio, Tadashi
    Kodama, Nobuhiro
    Uchida, Yujiro
    Ikeda, Nobuhiro
    Shinoda, Masahiro
    Nakagawa, Atsushi
    Nakatsumi, Hiroki
    Horiguchi, Tomoya
    Iwata, Mitsunaga
    Matsuyama, Akifumi
    Banno, Sumi
    Koseki, Takenao
    Teramachi, Mayumi
    Miyata, Masami
    Tajima, Shigeru
    Maeki, Takahiro
    Nakayama, Eri
    Taniguchi, Satoshi
    Lim, Chang Kweng
    Saijo, Masayuki
    Imai, Takumi
    Yoshida, Hisako
    Kabata, Daijiro
    Shintani, Ayumi
    Yuzawa, Yukio
    Kondo, Masashi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (12)
  • [28] A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19
    Fowotade, Adeola
    Bamidele, Folasade
    Egbetola, Boluwatife
    Fagbamigbe, Adeniyi F.
    Adeagbo, Babatunde A.
    Adefuye, Bolanle O.
    Olagunoye, Ajibola
    Ojo, Temitope O.
    Adebiyi, Akindele O.
    Olagunju, Omobolanle I.
    Ladipo, Olabode T.
    Akinloye, Abdulafeez
    Onayade, Adedeji
    Bolaji, Oluseye O.
    Rannard, Steve
    Happi, Christian
    Owen, Andrew
    Olagunju, Adeniyi
    FRONTIERS IN MEDICINE, 2022, 9
  • [29] Prognostic significance of serum galectin-3 in hospitalized patients with COVID-19
    Ozcan, Sevgi
    Donmez, Esra
    Yavuz, Sevil Tugrul
    Ziyrek, Murat
    Ince, Orhan
    Kucuk, H. Suat
    Tasdemir, Zeynep Atam
    Yilmaz, Ishak
    Varol, Sinan
    Sahin, Irfan
    Okuyan, Ertugrul
    CYTOKINE, 2022, 158
  • [30] Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
    De Leeuw, Elisabeth
    Van Damme, Karel F. A.
    Declercq, Jozefien
    Bosteels, Cedric
    Maes, Bastiaan
    Tavernier, Simon J.
    Detalle, Laurent
    Smart, Trevor
    Glatt, Sophie
    Debeuf, Nincy
    Deckers, Julie
    Lameire, Sahine
    Vandecasteele, Stefaan J.
    De Neve, Nikolaas
    Demedts, Ingel K.
    Govaerts, Elke
    Knoop, Christiane
    Vanhove, Karolien
    Moutschen, Michel
    Terryn, Wim
    Depuydt, Pieter
    Van Braeckel, Eva
    Haerynck, Filomeen
    Hendrickx, Tine C. J.
    Parrein, Vanessa
    Lalla, Marianna
    Brittain, Claire
    Lambrecht, Bart N.
    RESPIRATORY RESEARCH, 2022, 23 (01)
12345